LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News REGULATION FLASH L impact Sep 25, 2026, 09:44 PM UTC

Regenlab Usa Inc Files For IPO - SEC Filing

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

No ticker tags on this item.

Related stories

US FDA approves AbbVie drug for Parkinson's disease in adults The health regulator's website showed the approval on Friday. M impact | REGULATION | Sep 25, 2026, 10:10 PM UTC FTC chair says AI developers may be liable for agents' conduct Andrew Ferguson said developers who instruct AI agents would likely be liable for harm, and said the FTC will use existing laws. He also said the agency is preparing a market study M impact | REGULATION | Sep 25, 2026, 10:10 PM UTC US FDA approves AbbVie's drug for Parkinson's disease The US Food and Drug Administration has approved AbbVie's NYSE:ABBV drug for Parkinson's disease in adults, the health regulator's website showed on Friday. L impact | REGULATION | Sep 25, 2026, 10:00 PM UTC FDA approves Atebrioz for fibrodysplasia ossificans progressiva in adults, pediatric patients FDA says Atebrioz (zilurgisertib) is approved for fibrodysplasia ossificans progressiva in adults and pediatric patients 12 years and older. The recommended dosage is 100 mg once d L impact | REGULATION | Sep 25, 2026, 09:50 PM UTC FDA Approves Atebrioz For Fibrodysplasia Ossificans Progressiva In Adults, Pediatric Patients FDA L impact | REGULATION | Sep 25, 2026, 09:48 PM UTC Boston Scientific's Imager II catheter recall classified as FDA Class I U.S. FDA said Boston Scientific reported two serious injuries and no deaths from the device defect, and the company decided to discontinue selling the product line. M impact | REGULATION | Sep 25, 2026, 09:45 PM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.